Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DELTALIN vs CALDEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
Oral bioavailability of calcitriol is approximately 70-90%.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
None.
None
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DELTALIN vs CALDEROL, answered by our medical review team.
DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DELTALIN and CALDEROL depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DELTALIN and CALDEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.